Italia markets close in 4 hours 59 minutes

XOMA Corporation (0M26.L)

LSE - LSE Prezzo differito. Valuta in USD.
Aggiungi a watchlist
20,28-7,20 (-26,19%)
Al 03:25PM BST. Mercato aperto.
Schermo intero
Chiusura precedente27,48
Aperto20,28
Denaro0,00 x N/D
Lettera0,00 x N/D
Min-Max giorno20,28 - 20,28
Intervallo di 52 settimane20,28 - 20,28
Volume20
Media VolumeN/D
CapitalizzazioneN/D
Beta (5 anni mensile)0,87
Rapporto PE (ttm)0,20
EPS (ttm)1,00
Prossima data utili02 nov 2022 - 07 nov 2022
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    XOMA Reports Second Quarter 2022 Financial Results and Highlights Recent Operational Events

    The completion of Regeneron’s acquisition of Checkmate Pharmaceuticals resulted in a $5 million milestone payment to Kuros, $2.5 million of which was paid to XOMA in July. Data from Rezolute and Day One led both companies to announce plans to move their assets into Phase 3 programs. Ended the second quarter of 2022 with cash of $83.2 million and no debt on its balance sheet. EMERYVILLE, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA), a biotech royalty aggregator playin

  • GlobeNewswire

    XOMA Declares Quarterly Preferred Stock Dividends

    EMERYVILLE, Calif., June 20, 2022 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced its Board of Directors has authorized the following cash dividends to holders of XOMA’s Series A and Series B Cumulative Preferred Stock: Holders of the 8.625% Series A Cumulative Perpetual Preferred Stock (Nasdaq: XOMAP) shall receive a cash dividend equal to $0.53906 per share. Holders of depositary shares, each representing 1/1000 of a share of XOMA’s 8.375% Series B

  • GlobeNewswire

    Kuros Biosciences: Completion of the Acquisition of Checkmate Pharmaceuticals by Regeneron Pharmaceuticals Triggers a $5 Million Milestone Payment

    Ad-hoc announcement pursuant to Article 53 of the SIX listing rules • $2.5 million of milestone to be paid to XOMA Corporation under royalty agreement SCHLIEREN (ZURICH), Switzerland, June 02, 2022 (GLOBE NEWSWIRE) -- Kuros Biosciences AG (“Kuros” or the “Company”), a leader in next generation bone graft technologies, notes the completion of the acquisition of Checkmate Pharmaceuticals (NASDAQ: CMPI) by Regeneron Pharmaceuticals (NASDAQ: REGN). The completion triggers a $5 million milestone paym